1. NCCU Academic Hub
  2. 學術產出
  3. Item

學術產出-期刊論文

文章檢視/開啟

書目匯出

Google ScholarTM

政大圖書館

引文資訊

TAIR相關學術產出

題名 Reconsidering Conflicts over Gene Patents in view of Taiwan Patent Law
作者 陳龍昇
Chen, Lung-Sheng
貢獻者 法學院
關鍵詞 gene patent; compulsory license; Myriad; research exemption; Taiwan Patent Act; patient access; patent eligibility
日期 2020-04
上傳時間 29-十一月-2024 14:04:02 (UTC+8)
摘要 This article discusses the legal and policy issues arising out of gene patents in light of the United States Supreme Court's Myriad decision. There are alternatives to an outright ban on all gene patents. This article proposes recommendations to accommodate the competing interests of patient access to beneficial technologies and gene patenting. In order to balance the competing interests of encouraging innovation while making gene-based medical treatment more accessible, a research exemption from patent infringement and compulsory licensing of a gene patent is suggested by referring to the Taiwan Patent Act. These solutions would ensure scientists and other groups the opportunity to use gene-related patents for the public interest or noncommercial purposes. The research exemption enables research on patented genes without the risk of being held liable for infringement, thereby promoting further advancement in the gene-related industry. The framework of a compulsory license ensures patient access to genetic treatment. These solutions, on the one hand, solve primary concerns surrounding gene patents, and on the other hand, maintain gene patent protection and the incentives needed to promote the progress of gene-related technologies.
關聯 Biotechnology Law Report, Vol.39, No.2, pp.100-112
資料類型 article
DOI https://doi.org/10.1089/blr.2020.29162.lsc
dc.contributor 法學院
dc.creator (作者) 陳龍昇
dc.creator (作者) Chen, Lung-Sheng
dc.date (日期) 2020-04
dc.date.accessioned 29-十一月-2024 14:04:02 (UTC+8)-
dc.date.available 29-十一月-2024 14:04:02 (UTC+8)-
dc.date.issued (上傳時間) 29-十一月-2024 14:04:02 (UTC+8)-
dc.identifier.uri (URI) https://nccur.lib.nccu.edu.tw/handle/140.119/154534-
dc.description.abstract (摘要) This article discusses the legal and policy issues arising out of gene patents in light of the United States Supreme Court's Myriad decision. There are alternatives to an outright ban on all gene patents. This article proposes recommendations to accommodate the competing interests of patient access to beneficial technologies and gene patenting. In order to balance the competing interests of encouraging innovation while making gene-based medical treatment more accessible, a research exemption from patent infringement and compulsory licensing of a gene patent is suggested by referring to the Taiwan Patent Act. These solutions would ensure scientists and other groups the opportunity to use gene-related patents for the public interest or noncommercial purposes. The research exemption enables research on patented genes without the risk of being held liable for infringement, thereby promoting further advancement in the gene-related industry. The framework of a compulsory license ensures patient access to genetic treatment. These solutions, on the one hand, solve primary concerns surrounding gene patents, and on the other hand, maintain gene patent protection and the incentives needed to promote the progress of gene-related technologies.
dc.format.extent 106 bytes-
dc.format.mimetype text/html-
dc.relation (關聯) Biotechnology Law Report, Vol.39, No.2, pp.100-112
dc.subject (關鍵詞) gene patent; compulsory license; Myriad; research exemption; Taiwan Patent Act; patient access; patent eligibility
dc.title (題名) Reconsidering Conflicts over Gene Patents in view of Taiwan Patent Law
dc.type (資料類型) article
dc.identifier.doi (DOI) 10.1089/blr.2020.29162.lsc
dc.doi.uri (DOI) https://doi.org/10.1089/blr.2020.29162.lsc